Mutations in genes encoding the ε, δ, β and α subunits of the end plate acetylcholine (ACh) receptor (AChR) are described and functionally characterized in three slow-channel congenital myasthenic syndrome patients. All three had prolonged end plate currents and AChR channel opening episodes and an end plate myopathy with loss of AChR from degenerating junctional folds. Genetic analysis revealed heterozygous mutations: εL269F and δQ267E in Patient 1, βV266M in Patient 2, and αN217K in Patient 3 that were not detected in 100 normal controls. Patients 1 and 2 have no similarly affected relatives; in Patient 3, the mutation cosegregates with the disease in three generations. εL269F, δQ267E and βV266M occur in the second and αN217K in the first transmembrane domain of AChR subunits; all have been postulated to contribute to the lining of the upper half of the channel lumen and all but δQ267E are positioned toward the channel lumen, and introduce an enlarged side chain. Expression studies in HEK cells indicate that all of the mutations express normal amounts of AChR. εL269F, βV266M, and αN217K slow the rate of channel closure in the presence of ACh and increase apparent affinity for ACh; εL269F and αN217K enhance desensitization, and εL269F and βV266M cause pathologic channel openings in the absence of ACh, rendering the channel leaky. δQ267E has none of these effects and is therefore a rare polymorphism or a benign mutation. The end plate myopathy stems from cationic overloading of the postsynaptic region. The safety margin of neuromuscular transmission is compromised by AChR loss from the junctional folds and by a depolarization block owing to temporal summation of prolonged end plate potentials at physiologic rates of stimulation.
INTRODUCTION
After the discovery of the autoimmune origin of myasthenia gravis in the 1970s (1), it was realized that defects of neuromuscular transmission occurring in a congenital setting and in the absence of antibodies against the acetylcholine receptor (AChR) have different etiologies. Until recently, the congenital myasthenic syndromes (CMS) were defined by clinical, morphological, and electrophysiological criteria. The syndromes identified in this manner included end plate (EP) acetylcholinesterase (AChE) deficiency (2, 3) , presynaptic abnormalities that affect the release (4) or size (5) of transmitter quanta, or postsynaptic abnormalities associated with marked AChR deficiency, or a kinetic abnormality of the AChR, or both (6) (7) (8) (9) . In each syndrome, the safety margin of neuromuscular transmission is compromised by one or more specific mechanisms (9) .
It was also hypothesized that a kinetic abnormality of AChR detected at the single channel level predicts a mutation involving one or more AChR subunits (7, 9) . This notion was subsequently confirmed by the discovery of mutations in two of the four homologous subunits of AChR, and in different structural domains of the subunits, that either increase (10, 11) or decrease (12) response to acetylcholine (ACh). In the slow-channel CMS (SCCMS), the increased response to ACh consists of prolonged opening episodes of the AChR channel. Here we report identification and functional characterization of mutations of AChR in three patients with SCCMS. In each patient, cationic overloading of the postsynaptic region caused by cholinergic overactivity results in an EP myopathy with loss of AChR due to destruction of the junctional folds and temporal summation of the prolonged end plate potentials results in a depolarization block at physiologic rates of stimulation. Despite this common final *To whom correspondence should be addressed pathway in pathogenesis, the mutations resulting in SCCMS are found in different AChR subunits, and even in different structural domains of the subunits. The findings reported here have implications for treatment of CMS, genetic counseling, and structure-function relationships of AChR.
RESULTS

Patients
Patient 1, a 16-year-old male, had myasthenic symptoms since early infancy involving ocular, trunkal and limb muscles. Since the age of 7, he also experienced intermittent episodes of respiratory insufficiency requiring ventilatory support. Patient 2, a 19-year-old female, had myasthenic symptoms since birth involving ocular, other cranial, and limb muscles. Patient 3, a 30-year-old female, had ocular muscle weakness since early childhood, limb muscle weakness since the age of 8, and scoliosis since the age of 10. She cannot walk more than 100 yards without having to rest and cannot climb stairs without assistance. Patients 1 and 2 have no history of similarly affected relatives; in Patient 3, the family history is consistent with autosomal dominant inheritance through three generations. All patients have negative tests for anti-AChR antibodies, a decremental electromyographic response on stimulation of motor nerves, and a repetitive compound muscle action potential response to single nerve stimuli, as seen in the SCCMS (6) or EP AChE deficiency (2) .
Morphologic observations
Ultrastructural studies in all three patients showed an EP myopathy typical of the SCCMS (6) with destruction of many junctional folds, widened synaptic spaces, degeneration of membranous organelles in the junctional sarcoplasm, and focal myofibrillar degeneration and sometimes vacuolar change near EPs. Ultrastructural localization of AChR with peroxidase-α-bungarotoxin (α-BGT) revealed a normal density of AChR on the crests of those junctional folds that were intact and loss of AChR where the folds were destroyed. Some fiber nuclei near EPs displayed condensed chromatin and were convoluted or fragmented, suggesting apoptosis (13). Abundant AChE activity was detected at all EPs.
Intracellular microelectrode studies
The number of transmitter quanta released by nerve impulse was normal in Patients 2 and 3 and fell in the low-normal range in Patient 1 (data not shown). In all three patients, miniature EP currents (MEPCs) decayed biexponentially, with one decay time that fell in the normal range and one that was 8-to 13-fold prolonged (Fig. 1) . The mean MEPC amplitude was reduced to 43-69% of the normal mean. EP potentials were even more prolonged than EP currents, extending to over 50 ms in duration. Indeed, in each patient at physiologic rates of stimulation consecutive EP potentials arose during the decay of the preceding potential resulting in staircase summation of progressively smaller potentials (data not shown). The prolonged EP currents and potentials suggested a kinetic defect in one or more populations of EP AChRs.
Patch-clamp analysis of EP AChR channels
To search for a kinetic defect of AChR, we recorded single channel currents from EPs of each SCCMS patient and compared the findings with those at 34 EPs from eight controls. Simple inspection of the recordings from each patient revealed a population of markedly prolonged channel events (Fig. 2, left) . On formal analysis, at control EPs both the open intervals and bursts had a very brief minor (τ 1 ) and longer major (τ 2 ) component, as previously described (14) . At the SCCMS EPs, open intervals and bursts had two components, τ 1 and τ 2 , similar to those observed at the control EPs, and a third component, τ 3 , that was 3-to 4-fold and 5-to 8-fold longer than the respective open interval and burst τ 2 (Table 1 and Fig. 2, right) . With 1 µM ACh, at control EPs there was no clear clustering of channel events but at SCCMS EPs long channel events frequently occurred in clusters separated by intervals ranging from 1.4-12 s (Patient 1), 0.8-10 s (Patient 2), and 3-40 s (Patient 3), suggesting increased desensitization (15) . In Patient 3, we also recorded channel events with 0.1 µM ACh and still detected clustering of long-duration channel events.
The above channel events at the SCCMS EPs, like more than 99% of channel events at normal EPs (14) , had a conductance of ∼60 pS. Approximately 30% of the channel events in Patient 1, 17% in Patient 3, and none in Patient 2 had a reduced conductance of ∼46 pS and prolonged burst open durations (8 ms), typical of AChRs containing the γ instead of the ε subunit (γAChR) (16) . In addition, about 7% of the 46 pS channels in Patient 3 had a prolonged burst open duration of 20 ms. As in a previously reported case of SCCMS (10), we detected clear immunostaining for γAChR at some EPs of Patient 1; we found no staining for γAChR in Patient 2, and only trace staining in Patient 3 (17) .
In each patient, the abnormally prolonged EP currents combined with a major class of prolonged ACh-evoked channel openings suggested a mutation in one or more AChR subunit genes. 
Mutational analysis
Patient 1. Single-strand conformation polymorphism (SSCP) analysis on polymerase chain reaction (PCR)-amplified fragments of genomic DNA encoding all exons and flanking intronic regions of the α, β, δ, and ε subunits revealed seven aberrant conformers; five of these were also observed in controls, but two were unique to the patient. Direct sequencing of the corresponding DNA fragments identified five heterozygous polymorphisms (see Table 2 ). The first aberrant conformer unique to the patient was due to a heterozygous C→G transversion in δ exon 8 at nucleotide 799 (δC799G) that converted a glutamine to a glutamate codon at position 267 (δQ267E) (Fig. 3A) . The other aberrant conformer unique to the patient was due to a heterozygous C→T transition in ε exon 8 at nucleotide 805 (εC805T) that converted a leucine to a phenylalanine codon at position 269 (εL269F) (Fig. 3B ). Both altered residues are in the M2 transmembrane domains that line the channel pore. The altered glutamine at 267 in the δ-M2 domain is conserved in the δ and ε subunits of humans and other species. The altered leucine at 269 in the ε-M2 domain is conserved in the human β, δ, and γ subunits and in the δ and ε subunits of other species (Fig. 3D) . δQ267E caused gain of a HinfI and εL269F loss of an MnlI site. Restriction analysis of DNA samples revealed that εL269F was present only in the patient whereas heterozygous δQ267E was present in the patient's asymptomatic mother and sister, indicating that heterozygous δQ267E was not sufficient to cause disease (Fig. 3C) . No DNA samples could be obtained from the patient's deceased father. δQ267E was not detected in 100 normal controls or 51 other unrelated CMS patients. εL269F was not detected in 100 normal controls but was observed in one of 51 unrelated CMS patients. The other CMS patient harboring εL269F was the same patient as that reported by Gomez and Gammack (18) .
To check for nucleotide changes that SSCP analysis might have missed, we sequenced the entire open reading frames of the α, β, δ, and ε subunits using cDNA fragments and found no other mutations, but found an additional heterozygous polymorphism in the 3′ untranslated region of the δ subunit (see Table 2 ).
Patient 2. SSCP of genomic DNA encoding all exons and flanking intronic regions of the α, β, δ, and ε subunits revealed two aberrant conformers; one was commonly observed in controls and one was unique to the patient. Sequencing of the corresponding DNA fragments identified a heterozygous polymorphism in δ exon 1 (see Table 2 ) and a heterozygous G→A transition in β exon 8 at nucleotide 796 (βG796A) that converted a valine to a methionine codon at position 266 (βV266M) (Fig. 4A) . The altered amino acid in the β subunit is in the M2 transmembrane domain and is the fourth residue C-terminal to the invariant leucine that may form the narrowest constriction of the channel (19) . The altered amino acid is conserved among other human AChR subunits and among the β subunits of other species (Fig. 4C ). Time constants, τ n , and relative areas, a n , for each component of bursts are presented as mean ± SE. Where a range is presented for a n , this parameter depended on the concentration of ACh. ND, not detected.
Screening for βV266M by allele-specific PCR using DNA obtained from family members, 51 unrelated CMS patients, and 100 normal controls revealed βV266M only in the patient (Fig.  4B) . Sequencing of the entire open reading frames in cDNA fragments of the α, β, δ, and ε subunits demonstrated no other mutations but identified two heterozygous polymorphisms: one in the signal peptide region of ε exon 2 and the other in the 3′ untranslated region of the δ subunit (as in Patient 1) (see Table 2 ).
Patient 3. SSCP analysis of all exons and adjacent introns of the α, β, δ, and ε subunits revealed seven aberrant conformers; six were also present in normal controls and one was unique to the patient. Direct sequencing of the corresponding DNA fragments identified six polymorphisms (see Table 2 ). The aberrant conformer unique to the patient was due to a heterozygous C→G transversion in α exon 6 at nucleotide 651 (αC651G) that converted an asparagine to a lysine codon at position 217 (αN217K) (Fig. 5A) . The altered asparagine is in the M1 transmembrane domain and is conserved among other human AChR subunits and among α subunits of other species (Fig. 5C ).
αN217K resulted in loss of a HincII site. HincII digestion of DNA samples obtained from other family members showed the mutation cosegregating with the disease through three generations (Fig. 5B ). Restriction analysis detected no similar mutation in DNA samples of 100 normal controls and 51 other unrelated CMS patients.
To exclude the possibility that the αN217K mutation was only a linkage marker associated with an unidentified pathogenic mutation in the α subunit that SSCP might have missed, we sequenced the entire exons and the adjacent introns of the α subunit. No other mutations or polymorphisms were detected.
To summarize, all three patients have heterozygous mutations in transmembrane domains of AChR. Patient 1 has an ε-and a δ-subunit mutation, both in the M2 domain, Patient 2 a β-subunit mutation in M2, and Patient 3 an α-subunit mutation in M1. Therefore, we designed expression studies to determine the effects of each mutation on the expression, ACh binding affinity, and kinetic properties of AChR.
Expression studies
To evaluate pathogenicity of the four mutations, we engineered each mutation into the corresponding subunit cDNA of mouse AChR and coexpressed it with complementary wild-type subunit cDNAs in human embryonic kidney (HEK) fibroblasts. Measurements of α-BGT binding revealed robust expression of AChR containing each of the mutant subunits. Relative to wild type, amounts of α-BGT binding for the mutants were: 109 ± 22 % for αN217K, 109 ± 27 % for βV266M, 102 ± 33 % for εL269F, and 74 ± 11 % for δQ267E (mean ± SD of three experiments).
Patch-clamp recordings from HEK cells expressing the mutant AChRs revealed prolonged channel open intervals (Fig. 6 ) and bursts ( Fig. 6 and Table 3 ) for three of the four mutations: εL269F, βV266M and αN217K. The conductances of the mutant channels were identical to the conductance of wild-type channels as judged from single channel current amplitude at the standard holding potential of -70 mV. The increases in channel open durations depended on the mutation, and were similar but not identical to the increases observed in the corresponding patient (compare burst τ 3 in Table 1 with burst τ 2 in Table 3 ). Quantitative differences in kinetic parameters could arise from species differences (mouse versus human) or from different experimental conditions in the two sets of recordings. The mutation δQ267E showed normal open intervals and burst durations. Thus, the expression studies confirm pathogenicity of a mutation detected in each of the three patients.
The expression studies also revealed an unusually high rate of spontaneous channel openings for the two M2 domain mutations, εL269F and β266M, ranging from 1-3 events per second per patch. By contrast, no spontaneous openings were observed in wild-type AChR in recordings lasting from 20-30 min. Spontaneous openings were also observed with another mutation in the M2 domain, εT264P, which we previously reported to cause a CMS (10) . To be sure that spontaneous openings were obtained from a cell expressing the mutant AChR, we recorded currents from a second patch on the same cell but in the presence of ACh. In all cases, spontaneous and ACh-induced openings were observed in the same cell in the mutant AChRs but only ACh-induced openings in wild-type AChR. The major class of spontaneous openings, ranging in relative area from 0.77-0.91, had a mean duration of about 30 µs that coincided with that of the briefest of the three components of openings observed in the presence of ACh (Fig. 6 , right, and τ 0 in Table 3 ). The two longer components (τ 1 and τ 2 ) are thought to correspond to opening of singly and doubly occupied AChRs (10). Thus, spontaneous channel opening due to mutation of the M2 domain may contribute to pathogenicity.
To further evaluate pathogenicity of the mutations, we measured ACh binding at equilibrium by competition against the initial rate of 125 I-α-BGT binding. At equilibrium, binding of ACh includes contributions of resting, open channel, and desensitized states, each of which binds ACh with different affinity. Thus, a change in the contribution of one or more of these states can result in a change in apparent affinity for ACh. Three of the four mutations led to increases in affinity for ACh, ranging from 2-to 30-fold (Fig. 7) . The greatest increase in affinity was observed with the mutation in the M1 domain, αN217K; its binding profile coincided with that of the high affinity desensitized state of the wild type AChR (11), suggesting a much greater than normal extent of desensitization for this mutant. The relatively small two-fold increase in affinity produced by βV266M suggests little increase in the extent of desensitization, and may owe solely to the increased contribution of the high affinity open channel state. The nine-fold increase in affinity seen with εL269F may result from increases in the contributions of both open channel and desensitized states. The mutation δQ267E, which did not affect the duration of channel open intervals, also showed no change in ACh binding affinity. In the patient, both G and A nucleotides are present at position 796 (arrow), indicating heterozygous G→A transition. This mutation changes codon 266 from a GTG for valine to an ATG for methionine. (B) Allele-specific PCR using genomic DNA from blood of the family. Only the wild-type-allelespecific primer amplified the expected 221 bp fragment in the asymptomatic family members, whereas both the wild-type and mutant primers amplified the expected fragments in the patient, indicating that βG796A is a de novo mutation in the patient. Arrow indicates index patient. (C) Multiple alignment of AChR M2 membrane-spanning domains. Boxes enclose the conserved valine residues in human AChR subunits and in AChR β subunits of other species. The mutated methionine in the patient is shown by a bold letter.
DISCUSSION
We here report two new mutations, βV266M and αN217K, in adult muscle AChR subunit genes that cause SCCMS. We functionally characterize these as well as a third mutation, εL269F, previously reported by us (20) and also described by Gomez and Gamack (18) . In the patient studied by us, εL269F occurred together with δQ267E. We now show that δQ267E has no effect on AChR function. Therefore, it is a very infrequent polymorphism or, because its frequency in heterozygotes is less than 2%, a benign mutation (21) . αN217K is also noteworthy in that it occurs in the M1 transmembrane domain whereas the other SCCMS mutations described here or reported previously are in the M2 domain of different subunits or in the extracellular domain of the α subunit (10, 11) .
The present study reconfirms the notion that a kinetic abnormality of AChR is presumptive evidence for a mutation in one or more AChR subunit genes (9-11). In the cases investigated, a kinetic abnormality is indicated by abnormally prolonged decay of the end plate currents and by prolonged opening episodes of AChR channels. durations typical of γAChR. In Patient 3, however, about 7% of the 46 pS channels had an additional even longer component. This component can be readily explained by γAChR that harbor one or possibly two α subunits with αN217K. That the 46 pS channels represent immature γAChRs rather than a second pathogenic mutation is also evidenced by discovery of only one pathogenic mutation in each patient, by normal conductance of the expressed mutant channels, and by the immunocytochemical localization of γAChR at some EPs of Patients 1 and 3. Thus, all SCCMS mutations described in this as well as in previous reports (10, 11, 18, 20) can be attributed to a single mutation that causes a pathologic gain of function. However, mutations occurring in different domains of AChR exert their effect by different molecular mechanisms. 
Expression studies
The expression studies confirmed that three mutations, one detected in each of the three SCCMS patients, result in prolonged activation episodes of AChR and are therefore pathogenic. In addition, they allowed studies of the mutant AChRs in the absence of non-mutant or γ-subunit-containing AChRs. All four mutations lead to normal amounts of functional AChR in HEK cells, indicating a high probability of being present in functional AChRs at the synapse. Pathogenicity results from prolonged activation episodes caused by mutations in the M2 domain, εL269F and βV266M, and by mutation in the M1 domain αN217K. Increased spontaneous opening by the M2 mutations may also contribute to pathogenicity. The prolonged activation episodes are due in part to a slower than normal rate of channel closing, indicating stabilization of the open state by these mutations. Effects on opening rate or rate of ACh dissociation are also possible, but cannot be defined from the present studies. The increase in burst duration for each mutation correlates well with the time constant of the slowly decaying component in the MEPCs observed in the corresponding patient.
The expression system also allowed measurements of equilibrium ACh binding, which can detect changes in the contributions of high affinity open channel or desensitized states. Each of the pathogenic mutations lead to increased apparent affinity for ACh. The apparent affinity of the βV266M AChR increased two-fold relative to wild type, that for εL269F increased nine-fold, and that for αN217K increased 34-fold. A two-fold increase in apparent affinity can be accounted for by about a 50-fold increase in the open channel equilibrium constant (22) ; although open channel equilibrium constants were not measured, the observed seven-to 41-fold increases in burst duration are sufficiently large to suggest increases in the open channel equilibrium constant of this magnitude. Increases in ACh affinity greater than about two-fold are therefore likely to be due to increased desensitization. Thus we hypothesize that the extent of desensitization is not altered by βV266M, is enhanced by εL269F, and is markedly enhanced by αN217K. Indeed, the extent of Figure 8 . AChR subunit mutations causing SCCMS. Three of the mutated residues (εT264P, εL269F, and βV266M) are in M2 transmembrane domains lining the channel pore and are between the leucine ring (solid circle) and the external vestibule of the channel (upper interrupted circle). αN217K is in a segment of M1 that likely lines the channel lumen and may face the lumen in the absence of ACh. These mutations slow the channel closing rate and have a variable effect on apparent agonist binding affinity. αG153S, which is in the extracellular domain near residues that contribute to agonist binding, enhances agonist binding affinity allowing an increased number of reopenings during ACh occupancy; by contrast, it only modestly affects channel gating rate constants. Schematic diagram of AChR is based on Unwin (43) and scheme of residues in M1 on Akabas and Karlin (25) . equilibrium desensitization by αN217K is expected to be near maximal, as its binding profile coincides with that of the fully desensitized AChR (11).
Implications for structure-function relationships of the AChR macromolecule
Both cryoelectron microscopy (19) and site-directed mutagenesis studies (23) indicate that the M2 transmembrane domain consists of two alpha helical regions joined in the center by an extended structure of approximately three residues. Within the extended structure is a highly conserved leucine residue (human αL251, βL262, δL265, εL261) that may form a hydrophobic barrier to ion flow. All three of the M2 mutations reported here, as well as the previously reported εT264P mutation (10) are within the outer helical region facing the synapse (Fig. 8) . The site of the mutation in the β subunit, V266, is the fourth residue in the C-terminal direction from the central leucine, is accessible to labeling reagents when converted to cysteine (23) , and is predicted to face the lumen of the channel. The site of the mutation in the ε subunit, L269, is the eighth residue C-terminal to the central leucine, is not affected by labeling reagents when converted to cysteine, but is predicted to face the lumen of the channel. The site of the mutation in the δ subunit, Q267, is the second residue C-terminal to the central leucine, is not susceptible to labeling reagents when converted to cysteine, and is predicted to face away from the lumen of the channel. The non-lumenal position of δQ267 or that the side-chain length of δE267 is unchanged may account for the lack of effect on ion permeation or gating when mutated to the negatively charged glutamate. Common features of the three pathogenic M2 mutations are location in the synaptic half of M2, positioning toward the channel lumen, and introduction of a larger side-chain. Pathogenicity of the three M2 mutations suggests a role for these residues in stabilizing both the open and closed states of the channel.
Site-directed mutagenesis studies suggest that the M1 transmembrane domain contributes to gating of the channel (24, 25) , perhaps comprising part of the gating apparatus through interaction with the nearby M2 domain. Located in the outer third of M1, αN217 is accessible to solvent in the absence of ACh but not in its presence, suggesting positioning toward the channel lumen in the resting state of the AChR (25) . Our expression studies with αN217K, which introduce a positive charge into each of the two α subunits, show stabilization of both the open and desensitized states. These findings further implicate the M1 domain in operation of the channel gating apparatus.
Effects on neuromuscular transmission
SCCMS can have several adverse effects on neuromuscular transmission. Cationic overloading of the postsynaptic region caused by the cholinergic overactivity results in an EP myopathy with loss of AChR due to destruction of the junctional folds (6, 26) . Abnormal channel openings occurring even in the absence of ACh might also contribute to the abnormal postsynaptic ionic milieu and therefore to the EP myopathy. The temporal summation of EP potentials at physiological rates of stimulation predicts a depolarization block of transmission, as has also been demonstrated in experimental organophosphate poisoning (27) . Finally, an increased proportion of the mutant AChRs is likely to become desensitized in the presence of AChE inhibitors (28) . The duration of the synaptic response is likely to determine the severity of the EP myopathy and the degree of depolarization block, whereas the variable desensitization of the different mutant AChRs in the presence of ACh will govern the adverse response to AChE inhibitors. It follows that AChE inhibitors, which are beneficial in myasthenic disorders caused by a decreased number of kinetically normal AChRs, should be avoided in the SCCMS. On the other hand, long-lived channel blockers that curtail the quantal conductance change may be of benefit.
The predominant effect of the above slow-channel AChR mutations, together with the previously reported εT264P mutation (10) , is to slow the rate of channel closure; a previously described αG153S mutation (11) in the extracellular domain of the α subunit prolongs channel open episodes primarily by enhancing the affinity for ACh, allowing repeated opening during ACh occupancy. These findings indicate genetic heterogeneity in the slow-channel syndrome and that multiple molecular mechanisms influence the duration of opening episodes of the AChR channel.
MATERIALS AND METHODS
Muscle specimens
Specimens of intercostal muscle were obtained intact from origin to insertion from the patients and from control subjects without muscle disease undergoing thoracic surgery. All human studies were in accord with the guidelines of the Institutional Review Board of the Mayo Clinic.
End plate studies
Morphology and cytochemistry. For electron microscopy, EPs were localized and analyzed by established methods (29) . Peroxidase-labeled α-BGT was used for the ultrastructural localization of AChR (30) . γ-AChR was immunolocalized in cryosections with an affinity-purified γ-subunit-specific antibody (17) (gift from Z. W. Hall) and a biotin-avidin-based detection system. This antibody recognizes AChR in fetal but not adult human muscle. Intracellular microelectrode studies. All studies were done at 22 ± 0.5_C. MEPC and EPP recordings and estimates of the number of transmitter quanta released by nerve impulse were obtained as previously described (31) .
Patch-clamp recordings from EP AChRs. These were performed at 22 ± 0.5_C in the cell-attached mode by a slight modification of the previously described method (10, 14) . For all patches, the membrane potential was set to -80 mV; when possible, recordings were also obtained at -40, -120, and -160 mV. These membrane potentials were achieved by applying a corresponding potential to the patch pipette, and assuming a resting potential of 0 mV; a null resting potential was confirmed by the absence of detectable channel events with 0 mV applied to the pipette. Channel currents were recorded at 10 kHz using an Axopatch 200A amplifier (Axon Instruments), digitized at 50 kHz, stored on hard disk, and analyzed using the program MacTac (Instrutech) at a final bandwidth of 5.8 kHz. Burst durations were determined by grouping openings separated by a specified closed time that misclassifies equal proportions of long closed times within bursts and short intervals between bursts (32). Dwell time histograms were plotted on logarithmic abscissa and fitted to the sum of exponentials by maximum likelihood (33) .
Mutational analysis
mRNA and DNA samples. mRNA was obtained using the Micro-FastTrack mRNA isolation kit (Invitrogen). First-strand cDNA was prepared from mRNA by using random hexamer primers with the cDNA Cycle kit (Invitrogen) and following the instructions of the manufacturer. Genomic DNA was isolated from proteinase/SDS digest of blood or muscle by phenol-chloroform extraction followed by ethanol precipitation (34) .
Polymerase chain reaction procedures. Published cDNA sequences of the human α (35), β (36), δ (37) and ε (38) subunit were used to design cDNA primers. PCR primers were designed to amplify each exon with its flanking regions of each subunit as previously described (10) . PCR conditions for each primer were optimized by varying Mg 2+ concentration and pH and by addition of 10% dimethyl sulfoxide for amplification of G + C-rich fragments. The typical PCR reaction mixture included 60 mM Tris-HCl (pH 8.5), 15 mM (NH 4 ) 2 SO 4 , 1.5-2 mM MgCl 2 , 0.10-0.25 mM each dNTP, 0.8 µM each primer, with 100 ng of DNA and 1.25 units of Taq DNA polymerase (Perkin-Elmer/ Cetus) in 50 µl. cDNA fragments were amplified by the nested PCR procedure using 1/50th of the first amplification product. The typical cycling protocol comprised (i) denaturation at 94_C for 2 min; (ii) 35 cycles of 94_C for 30 s, 55_C or 60_C for 30 s, 72_C for 3 min; and (iii) final extension at 72_C for 7 min. Positions of primers for amplifying DNA segments harboring mutations and polymorphisms are available on request.
Exon scanning by SSCP analysis. The 'cold' SSCP procedure was employed (39) with ∼500 ng of PCR-amplified DNA. Denatured SSCP samples were loaded on 4-20% gradient polyacrylamide gel, electrophoresed at 12_C, stained with ethidium bromide, and examined under ultraviolet light.
Sequence analysis. PCR-amplified fragments of genomic DNA or cDNA were purified by Wizard PCR Preps (Promega). Plasmids were purified by QIAwell 8 Plus Plasmid kit (Qiagen). DNA fragments and plasmids were sequenced with an Applied Biosystems model 373A DNA sequencer using fluorescently labeled dideoxy terminators.
Allele-specific PCR. The βV266M mutation was identified by allele-specific PCR. The respective wild-type and mutant sense primers were 5′-CCCTGCTGACCCTTAaTG-3′ and 5′-CCCTGCTGACCCTTAaTA-3′ in β exon 8, 'a' representing a deliberately mismatched nucleotide to avoid misannealing of the primer to the opposite allele. The antisense primer was 5′-GTTGGAG-GAGGAGATCTTTC-3′ in β intron 8. The length of the expected amplicon was 221 bp. The PCR reaction mixture contained 2.0 mM MgCl 2 , 0.25 mM each dNTP, 10% dimethyl sulfoxide and the annealing temperature was 55_C. Other PCR conditions were as described above.
Restriction enzyme analysis. The δQ267E mutation resulted in gain of HinfI site, the εL269F mutation in loss of an MnlI site, and the αN217K mutation in loss of a HincII site. Using genomic DNA, a 163 bp fragment spanning δQ267E was amplified with primers 5′-CCAAGGTCACAGCTAAGTCTG-3′ and 5′-CGGG-CTTGAGCGTCACTC-3′; a 188 bp fragment spanning εL269F was amplified with primers 5′-CCGCTCTCACTGGCTCTC-3′ and 5′-CCCCCACCCTTCACACTG-3′; and a 306 bp fragment spanning αN217K was amplified with primers 5′-CCAAACCTC-ACTTCCTTTCT-3′ and 5′-AGACCCATCAGCGTCAGC-3′. After purification of the PCR products by ethanol precipitation, restriction enzyme digestion was carried out at 37_C for 2 h by adding 5 units of each enzyme in 20 µl of reaction mixture. The digested fragments were size-fractionated either on 4% agarose gel containing ethidium bromide (αN217K) or on 20% acrylamide gel (δQ267E and εL269F) and then stained with ethidium bromide.
Expression studies
Construction and expression of wild type and mutant AChR.
Mouse AChR subunit cDNAs were generously provided by Drs John Merlie, Norman Davidson [α, β, and δ subunits; referenced in (40) ] and Paul Gardner [ε subunit; referenced in (41)] and were subcloned into the CMV-based expression vector pRBG4 as described (40) . The εL269F and αN217K mutations were constructed by bridging restriction sites with synthetic double stranded oligonucleotides harboring the mutations. For εL269F, a 65 bp oligonucleotide bridged from a NheI to a BspMI site, whereas for αN217K, a 31 bp oligonucleotide bridged from a HincII to a SapI site. The βV266M and δQ267E mutations were constructed by overlap PCR mutagenesis. For βV266M, the final amplified fragment of 270 bp was ligated between NsiI and BglII sites, whereas for δQ267E the final amplified fragment of 580 bp was ligated between KpnI and NdeI sites. The presence of each mutation and the absence of unwanted mutations was confirmed by dideoxy sequencing. Human embryonic kidney fibroblasts (293 HEK) were transfected with mutant or wild type AChR subunit cDNAs using calcium phosphate precipitation as described (41) .
Patch-clamp recordings from AChRs expressed in HEK cells.
The methods were similar to those employed at the EP except that the bath and pipette solutions contained (in mM): KCl 142, NaCl 5.4, CaCl 2 1.8, MgCl 2 1.7, HEPES buffer 10, pH 7.4, with the pipette solution containing specified concentrations of ACh. Recordings were made with a membrane potential of -70 mV. Single channel currents were recorded at a bandwidth of 50 kHz, digitized with a pulse code modulation adapter at 94 kHz (VR-10B, Instrutech Corp.), transferred to a Macintosh computer using the program Acquire (Instrutech Corp.), and analyzed with the program MacTac at a final bandwidth of 8 kHz. Burst durations were determined by grouping openings separated by an interval greater than a specified closed time (100-150 µs), which was taken as the intersection of the briefest closed time component with the next longer component. 
